Company Information

  

Address: FIRST FLOOR, BLOCK 3, THE OVAL,
SHELBOURNE ROAD, BALLSBRIDGE 
City: DUBLIN 
State:  
Zip Code: 00000 
Telephone: 353 1 6699 020 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Amarin is a clinical-stage biopharmaceutical company with a lead program entering Phase 3 for hypertriglyceridemia. Amarin's cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin's pipeline also includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease and epilepsy, all of which are available for partnering. Amarin is listed in the U.S. on the NASDAQ Capital Market ("AMRN"). For more information please visit www.amarincorp.com.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-0.27NAN/E
06/2017-0.31NAN/E
03/2017-0.33NAN/E
12/2016-0.41NAN/E
09/2016-0.43NAN/E
06/2016-0.53NAN/E
03/2016-0.81NAN/E
12/20150.83NA2.28

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.07Total Liab/Total Assets1.05
Net Inc/Total Assets-0.52Total Liab/Inv Cap2.96
Net Inc/Inv Cap-1.45Total Liab/Comm Equity0.15
Pretax Inc/Net Sales-0.59Interest Coverage Ratio-3.09
Net Inc/Net Sales-0.66Curr Debt/Equity-3.45
Cash Flow/Net Sales-0.55LTD/Equity-9.40
SG&A/NetSales0.86Total Debt/Equity-12.86
Asset Utilization   Liquidity  
Net Receivables Turnover7.69Quick Ratio1.65
Inventory Turnover1.74Current Ratio1.92
Inventory Day Sales0.00Net Rec/Curr Assets0.14
Net Sales/Work Cap1.86Inv/Curr Assets0.14
Net Sales/PP&E1667.74  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 47.36 45.24 34.64 38.70
Cost of Goods Sold 11.92 11.40 8.20 10.16
Selling & Admin Exps 33.19 31.55 34.17 31.23
Operating Income -8.45 -11.40 -18.56 -12.86
Interest Exp 2.40 2.32 2.38 2.42
Pretax Income -10.83 -13.63 -20.94 -15.15
Other Income 0.03 0.08 -0.01 0.13
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -10.83 -13.63 -20.94 -27.45

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 79.69 86.06 96.68 98.85
Receivables - Total 34.61 37.48 29.45 19.99
Inventories - Total 28.55 24.81 23.88 20.51
Total Current Assets 147.03 150.43 154.79 146.33
Net Property, Plant & Equipment 0.04 0.05 0.07 0.08
Total Assets 166.61 170.19 175.20 167.00
Liabilities        
Accounts Payable 67.43 65.56 59.55 43.78
Debt in Current Liabilities 20.42 19.29 17.20 31.30
Total Current Liabilities 90.07 86.29 77.94 76.25
Long-Term Debt 104.50 108.17 111.24 85.16
Total Liabilities 212.72 208.95 203.97 176.06
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 24.36 24.36 24.36 24.36
Common Stock 208.64 208.56 208.47 207.17
Retained Earnings -1,249.40 -1,238.58 -1,224.95 -1,204.00
Treasury Stock -4.05 -3.90 -3.73 -1.50
Total Stockholders' Equity -46.11 -38.76 -28.77 -9.06
Total Liabilities and Stockholders' Equity 166.61 170.19 175.20 167.00

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -6.28 -10.50 -13.92 -19.31
Net Cash Provided by Investing Activities 0.00 0.00 -0.01 0.00
Net Cash Provided by Financing Activities -0.10 -0.11 11.75 0.00

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-179.18-1.24
12/201326.35-166.23-1.28
12/201454.20-56.36-0.36
12/201581.76-115.200.83
12/2016130.08-86.35-0.41
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17127108,84740.18




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.